1746-1747 / 2437
AZD1775 Phase 0 Study for GBM
Presented by:
Nader Sanai, MD
Initial Resection
Recurrence
& Enrollment
Preoperative Day 1
Single Dose
(100/200/400mg)
8 Hours Post-Dose
12 Hours Post-Dose
16 Hours Post-Dose
TUMOR BLOOD
Dose-Escalation Arm (n=12)
TUMOR
BLOOD
BLOOD
BLOOD
Phosphorylated H2AX
Phosphohistone-3
Cleaved Caspase-3
Cyclin E
Phospho-Cdk1
p53-Status
Checkpoint Regulators
Transport Proteins